Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amicus Therapeutics (FOLD) Retained Earnings (2016 - 2025)

Historic Retained Earnings for Amicus Therapeutics (FOLD) over the last 17 years, with Q3 2025 value amounting to -$2.8 billion.

  • Amicus Therapeutics' Retained Earnings changed 0.0% to -$2.8 billion in Q3 2025 from the same period last year, while for Sep 2025 it was -$2.8 billion, marking a year-over-year change of 0.0%. This contributed to the annual value of -$2.7 billion for FY2024, which is 209.03% down from last year.
  • Latest data reveals that Amicus Therapeutics reported Retained Earnings of -$2.8 billion as of Q3 2025, which was down 0.0% from -$2.8 billion recorded in Q2 2025.
  • Amicus Therapeutics' 5-year Retained Earnings high stood at -$2.1 billion for Q1 2021, and its period low was -$2.8 billion during Q3 2024.
  • Over the past 5 years, Amicus Therapeutics' median Retained Earnings value was -$2.6 billion (recorded in 2023), while the average stood at -$2.6 billion.
  • Per our database at Business Quant, Amicus Therapeutics' Retained Earnings tumbled by 1518.02% in 2021 and then changed by 0.0% in 2025.
  • Quarter analysis of 5 years shows Amicus Therapeutics' Retained Earnings stood at -$2.3 billion in 2021, then fell by 10.3% to -$2.5 billion in 2022, then decreased by 5.99% to -$2.7 billion in 2023, then dropped by 2.09% to -$2.7 billion in 2024, then decreased by 2.18% to -$2.8 billion in 2025.
  • Its Retained Earnings was -$2.8 billion in Q3 2025, compared to -$2.8 billion in Q2 2025 and -$2.8 billion in Q1 2025.